Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
Sun Pharma agrees to acquire Checkpoint Therapeutics
Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology treatments, for an aggregate upfront price of $355m.
Polyrizon Initiates Preclinical Studies
Raanana, Israel, -- Polyrizon Ltd., a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced the initiation of preclinical studies for intranas...
Roche Genentech Innovation Center Boston Launched at Harvard’s Enterprise Research Campus
The Roche Genentech Innovation Center Boston has been launched at Harvard’s Enterprise Research Campus in Allston, MA.
US tariffs on pharma imports can severely hit Indian firms: Experts
India currently levies around 10 per cent import duty on American drugs, while the US doesn't charge any import duty on Indian drugs.
UK’s pricing watchdog rejects Alzheimer treatments for the second time
The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision not to recommend the Alzheimer’s treatments Kisunla (donane...
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD
The FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.)
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
The company previously announced data from another Phase III trial of cebranopadol (developmental code GRT-6005), which also met its primary endpoint.
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
Ascentage Pharma said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications ...
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference
CERo Therapeutics Holdings, Inc. announced that it will present preclinical data for its lead compound, CER-1236, targeting ovarian cancer during the Spring Scientific meeting of the Society for Immun...
Indonesia approves Antengene’s Xpovio NDA for multiple indications
Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug and Food Control for three indications.
The acquisition will give Jazz access to Chimerix’s lead investigational candidate dordaviprone
Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash.
40
41
42
43
44
45
46
47
48
